Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
Journal Title: Journal of Vaccines & Immunization - Year 2015, Vol 3, Issue 2
Abstract
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardiovascular disease, pulmonary disease, or diabetes mellitus). This analysis is consistent with data suggesting immunocompetent at-risk populations aged ≥50 years produce functional anti-pneumococcal antibody responses to PCV13 comparable to those not at risk. An OPA titer that correlates with protection has not been defined for adults; however, PCV13 elicits generally higher responses than the 23-valent pneumococcal polysaccharide vaccine (PPSV23) one month after vaccination. PCV13 vaccination of immunocompetent at-risk populations likely results in benefits analogous to those without additional risk.
Authors and Affiliations
Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R, Gurtman A, Sundaraiyer V, Gruber WC, Scott DA, Isturiz RE
Keywords
Related Articles
- EP ID EP566654
- DOI 10.14312/2053-1273.2015-2
- Views 48
- Downloads 0
An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine
We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary...
Hospital epidemiology and costs of pertussis in France: A retrospective database analysis
Background: Pertussis vaccination coverage remains unsatisfactory in adults in France and pertussis is the leading cause of death due to bacterial infection in infants up to 3 months of age, whom are most often infected...
Impact of strategies and activities for reducing morbidity and mortality of vaccine-preventable diseases in Oman: A status report
Immunization is the only child survival strategy which alone averts two to three million deaths each year. This has been possible because of high coverages achieved by many countries in the world. Still nearly 1.5 millio...
Suboptimal vaccination rates in rural Ghana despite positive caregiver attitudes towards vaccination
Background: Vaccines save more than 3 million lives and prevent 750,000 disabilities each year. Optimum immunization coverage will help in the fight against infectious diseases. This study was carried out to characterize...
Developing a vaccine for human rhinoviruses
Rhinoviruses (RV’s) are common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are a major initiator of acute...